메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Iridium Awarded 5-Year System Infrastructure Transformation a…

New Contract Supports Enhancements to the Iridium and U.S. DoD EMSS Service Center and Related Facilities MCLEAN, Va., Dec. 2, 2025 -- Iridium Communications Inc. (NASDAQ: IRDM), a leading provider of global voice, data, and PNT satellite services, today announced it has been awarded a 5-year indefinite delivery/indefinite quantity (IDIQ) contract from United States Space Force's (USSF) Space Systems Command Commercial Space Office (COMSO) with a potential value of up to $85.8 million. The System Infrastructure Transformation and Hybridization (SITH) contract ena
- 김갑성 기자
- 2025-12-02 20:01
HoneyNaps' AI Sleep-Diagnosis Software SOMNUM™ Selected a…

[ 메디채널 김갑성 기자 ] Recognized at the official 2025 World Class Product of Korea Certification Ceremony held at Lotte Hotel World, Seoul Certification affirms SOMNUM's potential to lead the global market within seven years HoneyNaps accelerates global expansion: "We aim to become Korea's leading SleepTech innovator" BOSTON, Dec. 2, 2025 -- HoneyNaps, an AI-based sleep-medicine company, announced that its AI PSG Auto-scoring software SOMNUM™ has been designated as a 2025 Next Generation World Class Product by Korea's Ministry of Trade, Industry, and Resources (MOTIR) and
- 김갑성 기자
- 2025-12-02 19:00
Neusoft Medical Systems Unveils World's First 8cm Wide-Covera…

CHICAGO, Dec. 2, 2025 -- Neusoft Medical Systems Co., Ltd. ("Neusoft Medical"), a global leader in medical imaging, is showcasing its comprehensive portfolio of intelligent healthcare innovations at the Radiological Society of North America (RSNA) 2025 annual meeting. The highlight of the exhibition is the groundbreaking launch of the NeuViz P10, the world's first 8cm wide-coverage photon-counting CT. It is joined by several other high-end imaging systems and AI-integrated clinical solutions. The live demonstration presents a full-cycle intelligent imaging ecosystem s
- 김갑성 기자
- 2025-12-02 17:26
Antengene Announces IND Approval in China for Phase Ib/II…

SHANGHAI and HONG KONG, Dec. 2, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) i
- 김갑성 기자
- 2025-12-02 17:00
ZAGENO Receives Frost & Sullivan's 2025 Global Company of the…

[ 메디채널 김갑성 기자 ] ZAGENO earns global recognition for driving innovation, operational efficiency, and transformative customer value across the life sciences e-commerce ecosystem. SAN ANTONIO, Dec. 2, 2025 -- Frost & Sullivan is pleased to announce that ZAGENO has been recognized with the 2025 Global Company of the Year Recognition in the life sciences e-commerce industry for its outstanding achievements in digital innovation, customer value enhancement, and strategic market execution. This recognition highlights ZAGENO's consistent leadership in driving measurable outcomes, strengt
- 김갑성 기자
- 2025-12-02 15:00
Accord Healthcare Announces Launch of Denosumab∇ -…

∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025. Both medicines were approved by the European Medicines Agency (EMA) in September of this year following trials versus their reference product showing they are highly similar to the P
- 김갑성 기자
- 2025-12-02 15:00
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug…

HSINCHU, Dec. 2, 2025 -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvant AB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FDA) for its Type II Drug Master File (DMF). Amaran Biotech is now the first adjuvant supplier in Taiwan to obtain FDA DMF Acknowledgement. This milestone underscores the company's strong capabilities in adjuvant process development, quality management, and international regulatory compliance, while further enablin
- 김갑성 기자
- 2025-12-02 14:42
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO…

Officially recognized by WHO as a standard varicella vaccine strain alongside Oka Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its proprietary varicella vaccine strain MAV/06 has been included in the World Health Organization (WHO) Position Paper on varicella vaccination, published on November 21. WHO Position Paper serves as the most authoritative global guidance for immunization policy, developed by the Strategic
- 김갑성 기자
- 2025-12-02 13:00
쭐랄롱꼰대 개발 AI '딥 GI', 위장관암 진단 혁신 기대

[ 메디채널 김갑성 기자 ] 방콕 2025년 12월 2일 -- 쭐랄롱꼰대학교 의과대학이 공과대학과 협력해 '딥 GI(Deep GI)'라는 혁신적인 인공지능(AI) 기술을 개발했다. 이 기술은 일반의가 전문의와 동등한 수준으로 위장관암(胃腸管癌)을 발견하는 데 도움을 줄 수 있게 설계됐다. 수십만 건의 내시경 영상으로 훈련된 이 시스템은 태국 식품의약품국(Thai FDA) 승인을 획득해 현재 전국 배포 및 상업화 준비를 진행 중이다. 대장암은 태국인들 사이에서 세 번째로 흔한 암으로, 특히 50세 이상이 고위험군에 속한다. 그러나 태국에는 내시경 전문의가 약 1000명에 불과해 검진 수요를 충족할 만큼 잘 훈련된 전문 인력이 부족하다. 딥 GI는 내시경 검사 시 폴립(용종)과 같은 비정상 병변을 실시간으로 표시해주는 '조력자(co-pilot)' 역할을 수행하며 이러한 격차를 해소하는 데 도움을 준다. 이를 통해 의사는 보다 자신감 있고 효율적으로 최종 진단을 내릴 수 있게 된다. 2022년 완료된 딥 GI 1단계는 대장암 검출에 집중했다. 1단계의 성공은 2025년 6월 딥 GI 2단계 출시로 이어졌다. 2단계에서는
- 김갑성 기자
- 2025-12-02 10:45
Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers…

BANGKOK, Dec. 2, 2025 -- The Faculty of Medicine, Chulalongkorn University, in collaboration with the Faculty of Engineering, has developed "Deep GI," an artificial intelligence (AI) innovation designed to assist doctors in detecting gastrointestinal cancers with high standard performance equal to that of expert specialists. Trained on hundreds of thousands of endoscopic images, the system has received the Thai FDA approval and is being prepared for national deployment and startup commercialization. Colorectal cancer remains the third most common cancer among Thais, a
- 김갑성 기자
- 2025-12-02 10:40

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 20시 10분